Andapsin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Andapsin

Quick Facts

Property Description
Active ingredient Sucralfate
Form Tablets, oral suspension, granules
Pharmacological class Gastrointestinal agent, Cytoprotective agent
Common purpose Gastrointestinal mucosa protection
Origin Synthetic

Andapsin: Definition and Pharmacological Classification

Andapsin is the trade name for a prescription-only medicine (Rx) based on the single active ingredient, Sucralfate (INN), which primarily functions as a gastrointestinal agent. Sucralfate is clinically recognized as both a cytoprotective agent and an anti-ulcer agent, reflecting its specific role in providing defense for the cellular lining of the digestive tract. This agent is synthetic, chemically defined as an aluminum salt of sucrose octasulfate, a complex structure that pharmacological studies confirm enables a targeted, localized protective function within the digestive system. Its non-systemic nature represents a key differentiation, focusing its therapeutic impact entirely within the gastrointestinal lumen.

Composition, Forms, and General Purpose

The medication is exclusively for oral route administration and is supplied in various dosage forms, including tablets, oral suspension, and granules for oral suspension. This variety ensures suitable administration options for adult patients. The core component, Sucralfate, is characterized by minimal absorption into the bloodstream, a key property that means the drug's action is highly localized. The general purpose is to establish a robust physical defense, consistently supported by clinical evidence, to shield vulnerable or damaged areas of the mucosa from corrosive elements.

How Sucralfate Provides Localized Gastroprotection

The overall benefit of Sucralfate stems from its specific mechanism of localized gastroprotection. When the drug encounters the acidic environment of the stomach, it rapidly transforms into a dense, highly viscous, and adhesive paste. This paste preferentially binds to proteinaceous material exposed in injured tissue, such as an ulcer bed, forming a stable shield. This protective barrier is crucial not only for physical defense but also because it actively inhibits the corrosive effects of the digestive enzyme pepsin, offering a comprehensive local defense to facilitate the body’s natural healing processes.

Regulatory References

  1. Sucralfate: MedlinePlus Drug Information

What side effects are possible with Andapsin?

Possible Side Effects and Safety Information

The safety profile for this medicine, which contains sucralfate, is categorized by both its occurrence frequency in clinical trials and specific population constraints documented in official labeling. The effects are primarily related to the gastrointestinal system and are classified using standard regulatory frequency categories.


Frequency-Classified Adverse Reactions

The most frequently reported complaint in clinical trial data is constipation, which is officially classified as a common adverse reaction (incidence of 2%). Other documented adverse effects, reported in less than 0.5% of patients (uncommon), include:

  • Gastrointestinal: Diarrhea, dry mouth, flatulence, indigestion, nausea, vomiting.
  • Nervous System: Headache, dizziness, sleepiness, vertigo, and insomnia.
  • Skin/Other: Pruritus (itching), rash, and back pain.

Serious Safety Considerations and Special Populations

Official regulatory documents detail several critical safety considerations, often related to the aluminum component of sucralfate:

  • Renal Impairment: The drug must be used with caution in patients with chronic renal failure or those on dialysis. Impaired kidney function can lead to reduced excretion of the absorbed aluminum, increasing the risk of aluminum accumulation and toxicity (including osteodystrophy and encephalopathy).
  • Hypersensitivity and Bezoars: Post-marketing surveillance has documented rare, severe hypersensitivity reactions (e.g., laryngeal edema, anaphylaxis) and cases of bezoar formation (a mass of undigested material) in patients with predisposing conditions.
  • Administration Constraint: The medicine must be administered only by the oral route. Fatal complications, including cerebral and pulmonary emboli, have been reported following inappropriate intravenous administration of the oral suspension.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information states that acute oral overdose of Sucralfate is generally asymptomatic because the drug is only minimally absorbed from the gastrointestinal tract. Due to limited human experience with overdosage, no specific treatment recommendations can be given, and risks associated with acute overdose should be minimal.

In rare reports where adverse events were described, overdose symptoms have included dyspepsia, abdominal pain, nausea, and vomiting.

Serious Risks and Emergency Action

Chronic high-dose exposure or prolonged use presents a specific concern regarding aluminum accumulation in the body. This accumulation, linked to the aluminum component of Sucralfate, is associated with documented severe outcomes affecting the central nervous system (e.g., encephalopathy) and the skeletal system (e.g., osteodystrophy).

The risk of aluminum-related toxic reactions is greater for patients with impaired renal function (including those on dialysis), as they have difficulty excreting the small amounts of absorbed aluminum.

For any suspected overdose, seek immediate medical attention. If the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened, immediately call emergency services. Management is typically symptomatic and supportive.

Therapeutic Uses of Andapsin

What Andapsin Treats: Main Uses and Benefits

Relieving Pain and Burning in the Upper Digestive Tract

This medication is commonly used to help manage symptoms related to physical discomfort in the upper gastrointestinal tract, such as pain, burning, or irritation originating from the lining of the stomach and small intestine. It helps address symptom clusters that interfere with daily comfort and are linked to inflammatory or irritative states. By addressing these distressing symptoms, it provides support that helps ease the overall symptom burden and supports the patient during episodes of heightened discomfort.


Promoting Healing for Ulcers and Erosions

Andapsin is primarily relevant in conditions involving inflammatory or irritative processes, particularly those characterized by the presence of ulcers or erosions on the digestive tract lining, such as duodenal ulcers and gastric ulcers. The medicine is commonly used to help with symptoms related to these conditions. It is often used when supportive symptom management is appropriate. The medication is applied when appropriate for managing symptoms that interfere with daily comfort, and may assist with maintaining functional stability during symptomatic phases.

Quick Fact: Supports Easing of Pain and Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Andapsin? (Sucralfate)

The official regulatory profile defines eligibility for Andapsin (Sucralfate) based on age, organ function, and pre-existing conditions.

Contraindications and Restrictions

Population Group Eligibility Status Regulatory Requirement
Hypersensitivity Contraindicated Patients with known allergy to Sucralfate or its excipients must not use this medicine.
Pediatric Patients Not Established Safety and effectiveness have not been established in children and adolescents.
Chronic Renal Failure Conditional Use Use must be with caution due to the risk of aluminum accumulation in the body.
Pregnancy Conditional Use Permitted only if clearly needed, as adequate studies in pregnant women are lacking.
Nursing Mothers Caution Advised Caution should be exercised, as it is not known whether the drug is excreted in human milk.

Adults are the established population for use. Special caution is required for older adults due to the higher frequency of reduced renal function. Conditional use is also necessary for patients with certain pre-existing conditions, such as delayed gastric emptying or dysphagia (difficulty swallowing), due to the documented risk of bezoar formation or aspiration, respectively.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Andapsin’s interaction profile is officially characterized by a nonsystemic pharmacokinetic mechanism where the active ingredient, sucralfate, binds to co-administered agents in the gastrointestinal tract, resulting in a reduction of their absorption and bioavailability.

Interaction Type Affected Substances / Products Official Constraint
Reduced Absorption Cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, L-thyroxine, phenytoin, ranitidine, theophylline, and others. The concomitant medication should be administered 2 hours prior to sucralfate to eliminate this interaction.
Additive Exposure Aluminum-containing products, such as antacids. Increases the total body burden of aluminum.

This requirement for timing separation is critical. Antacids must not be administered within 30 minutes before or after Andapsin. Co-administration with enteral tube feedings should also be separated by at least 1 hour due to the documented risk of bezoar formation.

A population-specific interaction consideration exists for chronic renal failure and dialysis patients. Due to impaired aluminum excretion, the use of Andapsin, especially with other aluminum-containing products, must be approached with caution due to the increased risk of aluminum accumulation as described in official documents. Post-marketing reports also suggest that antidiabetic agents may require adjustment, although the exact mechanism is not fully defined.

Mechanism of Action

How Andapsin Works

Andapsin (Sucralfate) exerts its effect through a highly localized, pH-dependent, dual mechanism that combines immediate physicochemical protection with the active enhancement of intrinsic healing pathways.


️ Immediate Physicochemical Protection

This domain covers the drug’s direct, non-systemic interaction within the gastrointestinal lumen. When exposed to gastric acid ( pH < 4), Sucralfate rapidly transforms into a viscous, polyanionic gel that selectively binds to the exposed proteins at the base of damaged tissue. This binding creates a stable physical barrier that simultaneously prevents H^+ ion back-diffusion and physically inhibits the proteolytic activity of the enzyme pepsin, which prevents chemical disruption of the mucosal proteins.


Endogenous Cytoprotection and Tissue Repair

This mechanistic domain involves the drug’s localized influence on the body's defensive and reparative signaling pathways. The drug enhances the local synthesis and release of prostaglandin E2 ( PGE2), which corresponds to increased secretion of protective mucus and bicarbonate ( HCO3^-) at the epithelial surface. Concurrently, Sucralfate protects and concentrates endogenous growth factors (e.g., EGF) at the injury site, thereby facilitating epithelial cell proliferation, migration, and the physiological cascade required for tissue regeneration. This mechanism is functionally dependent on the acidic environment and is weakened by excessive pH elevation.

Dosage and Administration Information

How to Use Andapsin: Official Administration Guidelines

Andapsin (Sucralfate) usage focuses on administration route, timing, and dosing frequency. The medication is strictly intended for oral administration only; the oral suspension must not be administered intravenously.


Administration Scope

Parameter Official Instruction
Route of Administration For oral administration only.
Dosing Schedule (Adults) Active Duodenal Ulcer: 1 gram four times a day. Duodenal Ulcer Maintenance: 1 gram twice a day.
Timing in Relation to Meals Must be taken on an empty stomach. Administration is typically one hour before or two hours after meals.
Preparation Requirements The oral suspension must be shaken well before each use.

Procedural and Population-Specific Conditions

Administration requires careful timing to ensure the drug's localized action. Sucralfate should not be taken within 2 hours of other critical oral medications to prevent interference with drug absorption. Similarly, antacids should not be administered within one-half hour of the Sucralfate dose.

Treatment for an active duodenal ulcer is typically continued for 4 to 8 weeks or until healing is objectively confirmed. Maintenance therapy to prevent recurrence may continue for up to 12 months.

In older adults, dose selection should be cautious, generally starting at the low end of the dosing range. For pediatric patients, the safety and effectiveness have not been established.

Recent Clinical Evidence

Research evidence / Overview of Studies for Andapsin (Sucralfate)

This overview summarizes the available research and clinical trials conducted for Andapsin (Sucralfate), focusing on the types of studies performed, the outcomes researchers measured, and where evidence may still be limited. This information is based on authoritative governmental and scientific sources and is not intended as medical advice.


Evidence for use in Active Duodenal Ulcer Healing

Research for the short-term use of Andapsin in duodenal ulcers primarily involved randomized controlled trials (RCTs). Researchers examined the endoscopic rate of complete ulcer resolution and how patients reported changes in physical discomfort over the study period, typically four to eight weeks. Trials reported differences in healing rates between the treatment groups and those who received an inactive placebo. Comparative research examined healing patterns and described them as comparable to those observed with certain older prescription anti-ulcer medications. The evidence is generally limited in duration, and long-term outcomes following the acute treatment phase are not well characterized in these specific trials.


Evidence for Prevention of Duodenal Ulcer Recurrence (Maintenance)

Studies for preventing ulcer return have used long-term, placebo-controlled, randomized trials. These explored whether continued use of the medicine was studied for its association with fewer ulcers returning. Research data show patterns related to ulcer recurrence that were lower in the treatment groups compared to those receiving placebo. While the data show patterns related to reduced recurrence compared to no treatment, comparative evidence against current first-line therapeutic strategies remains limited. Optimal duration for maintenance therapy is a subject that extends beyond the scope of these specific recurrence trials.


Research Gaps and Areas of Uncertainty

Research for active gastric ulcers involves similar RCT designs, but the available evidence volume is smaller than the duodenal ulcer data. Certainty remains low regarding how Sucralfate compares directly to current first-line gastric ulcer treatments. Furthermore, data for certain groups remain insufficient, such as information for special populations like children. The evidence for other contexts focuses on research scenarios where the medicine was observed concurrently with other treatments. Research provides context but not individual predictions regarding personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Andapsin (FAQ)

Q: How quickly should I expect to notice any effects from Andapsin?

According to official clinical summaries, the protective effect of Andapsin (Sucralfate) is typically established within 1 to 2 hours after it is administered. This time frame reflects when the medicine begins to form its localized physical barrier at the site of the ulcer.

Q: Are there any common supplements that should not be taken with Andapsin?

Official information indicates that, like other oral medicines, certain supplements may have their absorption reduced if taken at the same time as Andapsin. Specific supplements, such as multivitamins or Vitamin D, may also interact with the drug's aluminum component. A time separation of at least 2 hours between the medicine and supplements is described in the official guidance for preventing absorption interactions with other oral agents.

Q: Will Andapsin interact with my daily pain reliever?

The official prescribing information notes that Andapsin can bind to and reduce the absorption of several oral medicines. If you take a common oral pain reliever, such as an NSAID (like naproxen), the official guidance for this type of drug-drug binding interaction indicates that separating administration by at least 2 hours helps prevent a delay in the onset of action for the pain reliever.

Q: Can Andapsin be used by people who have diabetes?

Caution is advised when the oral suspension form of Andapsin is used by patients with diabetes, as reports of hyperglycemia (high blood sugar) have been documented. The official product information mentions that clinical monitoring of blood glucose levels and possible dosage adjustments for antidiabetic agents have been documented as potential requirements.

Q: Is there a generic version of Andapsin available?

Yes, the trade name Andapsin is based on the active ingredient Sucralfate. Sucralfate is the generic name and is widely available in multiple generic tablet and suspension formulations worldwide.

Q: Is Andapsin suitable for people who are sensitive to certain dyes or fillers?

Hypersensitivity (an allergic reaction) to Sucralfate or any of its inactive ingredients (excipients) is a contraindication for use. Since different generic and brand formulations may contain various dyes or fillers, the inactive ingredient list of a specific product is the source for patients with known sensitivities to review.

Q: Can people who are lactose intolerant take Andapsin?

Lactose is not universally listed as an excipient (filler) in all Sucralfate formulations, but ingredients can vary widely between products. For confirmed lactose intolerance, the inactive ingredient list on the specific package or product insert contains the information necessary for individuals to review.

Q: What is the difference between Andapsin and an antacid?

Andapsin is classified as a cytoprotective agent because it creates a physical barrier to protect damaged tissue. This mechanism is primarily localized, meaning the medicine is minimally absorbed into the body. This is distinct from an antacid that works by chemically neutralizing existing stomach acid.

Q: Is it safe to drive or operate machinery after taking Andapsin?

Official safety information notes that due to the potential for side effects such as dizziness or sleepiness, caution concerning activities like driving or operating heavy machinery may be relevant. These effects have been documented in official adverse reaction summaries.

Q: How is the effect of Andapsin different from medicines that reduce stomach acid?

Andapsin's effect is to physically protect the gastrointestinal lining from corrosive elements like acid and pepsin. Its mechanism is localized and physical, relying on the acidic environment to activate. This differs from medicines that reduce stomach acid systemically (like proton pump inhibitors or H2 blockers).

Q: Are there specific food items or beverages that interact with Andapsin?

While official guidance does not identify specific food items that interact with the medicine, the timing of administration is critical. Administration on an empty stomach is required according to official guidelines to ensure the medicine can coat the ulcer site properly.

Q: Are there any reported interactions between Andapsin and alcohol?

Official documents do not cite a direct pharmacological interaction between Sucralfate and alcohol. Because alcohol is a known irritant to the intestinal lining, reducing or avoiding alcohol intake is often cited as a general principle when managing ulcers, regardless of the medicine being used.

Q: How does Andapsin compare to the older generation of GI protectants?

Clinical research has compared Andapsin to certain older acid-reducing agents in specific clinical scenarios, such as preventing stress ulcers in high-risk patients. Some evidence suggests that Andapsin may be associated with a lower incidence of ventilator-associated pneumonia (VAP) in these settings compared to those older agents.

Q: Do official prescribing documents mention specific dietary restrictions while taking Andapsin?

Official information does not impose specific dietary restrictions while taking this medicine. The most important administrative rule is the timing, as the medicine is required to be taken on an empty stomach, separated from meals by one to two hours.

Q: What happens if I stop taking Andapsin suddenly?

For the short-term treatment of an active duodenal ulcer, the available data on acute ulcer healing do not report that sudden cessation following a completed course influences the frequency or severity of future ulcer recurrence.

Q: Is Andapsin safe for people with liver disease?

Manufacturer labeling does not provide specific information regarding the use of Andapsin (Sucralfate) in individuals with hepatic impairment (liver disease). Therefore, caution is generally advised for this population.

Q: Does the time of day matter when taking Andapsin?

The official dosing schedule is structured to ensure consistent protection, typically recommending administration four times a day, which usually includes one dose taken at bedtime. The nighttime dose is considered important for coating the stomach lining during long periods without food intake.

Q: What kind of specialized monitoring is required when taking Andapsin for a long time?

Because Sucralfate contains aluminum and a small amount can be absorbed into the body, patients with chronic renal failure (severe kidney problems) or those on long-term treatment may require specific monitoring of their kidney function to avoid the risk of aluminum accumulation.

Q: What is the role of Andapsin in managing GERD (reflux)?

While the main approved use is for treating duodenal ulcers, official sources and clinical literature also cite Sucralfate as being used in the prevention and/or treatment of Gastro-Esophageal Reflux Disease (GERD).

Q: Are there different strengths of Andapsin tablets available?

According to the official drug labeling, the standard tablet strength for oral administration in the United States and similar markets is 1 gram (or 1000 mg) of Sucralfate.

Q: Is there official information about Andapsin and vision changes?

Yes, official post-marketing surveillance reports have documented cases of blurred vision as a possible adverse effect. While this change is documented, its exact frequency is not known.

How should Andapsin be stored and disposed of?

Andapsin (sucralfate) should be stored in a tightly closed container at room temperature, generally between 68 F and 77 F (20 C and 25 C). It is crucial to protect the medication from excess heat, moisture, and direct light.

Do not freeze the oral suspension form of this medicine, as freezing may affect its stability and effectiveness. Avoid storing any form of Andapsin in the bathroom due to potential humidity fluctuations.

Keep all forms of the medication out of the sight and reach of children and pets. Do not use the medicine after the expiration date. When disposing of unneeded or expired Andapsin, consult your pharmacist or healthcare professional for guidance on proper disposal methods in your area. This typically involves special programs or mixing with an undesirable substance before discarding in household trash, rather than flushing it down a toilet or sink, which can pose environmental risks.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Andapsin found in:

A-Z Index: